Taysha Gene Therapies, Inc. (TSHA) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Taysha Gene Therapies displays near-term hot idea potential driven by FDA Breakthrough Therapy designation, upcoming pivotal trial data, and a strong cash runway through 2028. Technical momentum is strong with a 42% gain over 21 days but overbought conditions suggest possible short-term consolidation. The substantial regulatory catalysts provide a clear short-term growth narrative.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Persistent losses ⢠High R&D burn TSHA's balance sheet is much strongerâcash $299.9M, current ratio 10.48 and cash exceeding debtâsubstantially reducing solvency risk, but persistent operating losses, minimal revenue and negative cash flow keep profitability and valuation under pressure.
Price Behavior
Key Price Behavior Insights: ⢠shallow downtrend ⢠defined short-term support ⢠lowâmoderate volatility Support Level: $4.48â$4.51 Resistance Level: $4.84â$4.89 Over the last month TSHA traded in a shallow downtrend (â3â4% decline to $4.49) holding near $4.48â$4.51 support â breach would signal continuation while strength above $4.84â$4.89 favors a bullish reversal amid lowâmoderate volatility.
Sentiment & News
Key News Insights: ⢠Executive onboarding ⢠Material equity grant ⢠Earnings date set Taysha granted 156,870 RSUs and a 134,460-share option to a new hire under its 2023 Inducement Plan and scheduled FY2025 results and a webcast for March 19, 2026.
AI Summary
Taysha has shifted from a speculative burn story to an outcomeâdriven biotech where TSHAâ102's REVEAL pivotal pathway and FDA Breakthrough alignment make the company's nearâterm valuation hinge almost entirely on a small, singleâarm interim analysis and timely PPQ execution. Investors should therefore focus on the 6âmonth interim readout and PPQ milestonesâpositive interim efficacy with onâschedule PPQ would materially deârisk value, while ambiguous results or manufacturing delays will likely force dilutive financing.
Description
Taysha Gene Therapies, Inc. is a clinical-stage company developing adeno-associated virus (AAV) gene therapies to treat monogenic disorders of the central nervous system. Its pipeline includes candidates targeting rare pediatric conditions such as giant axonal neuropathy, Rett syndrome, CLN1 disease, SLC13A5 deficiency and GM2 gangliosidosis. The company maintains a development and commercialization collaboration with UT Southwestern Medical Center and is headquartered in Dallas, Texas, having been incorporated in 2019.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 6 | Oct 13 | TSHA | Taysha Gene Therapies, Inc. | Taysha Gene Therapies displays near-term hot idea potential driven by FDA Breakthrough Therapy designation, upcoming pivotal trial data, and a strong cash runway through 2028. Technical momentum is strong with a 42% gain over 21 days but overbought conditions suggest possible short-term consolidation. The substantial regulatory catalysts provide a clear short-term growth narrative. | Closed | +14.2% |